Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer
| Autor: | William E. Gooding, Sakkaraiappan Ramalingam, Chandra P. Belani, M. K. Mohamed, Yan Lin |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms Risk Assessment Gastroenterology Drug Administration Schedule Statistics Nonparametric Gefitinib Predictive Value of Tests Carcinoma Non-Small-Cell Lung Internal medicine Confidence Intervals Humans Medicine Prospective Studies Pneumonectomy Lung cancer Prospective cohort study Survival analysis Aged Neoplasm Staging Probability Salvage Therapy Dose-Response Relationship Drug Performance status business.industry Hematology Exanthema Middle Aged Prognosis medicine.disease Survival Analysis Chemotherapy regimen Rash Surgery Treatment Outcome Oncology Chemotherapy Adjuvant Expanded access Quinazolines Female medicine.symptom business medicine.drug |
| Zdroj: | Annals of Oncology. 16:780-785 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdi157 |
| Popis: | Background: Gefitinib (Iressa®) is active as a single agent in the treatment of select patients with recurrent non-small cell lung cancer (NSCLC). The clinical characteristics of patients treated with gefitinib on an Expanded Access Program (EAP) at our institution identified predictive variables associated with better outcome. Patients and methods: Patients (n=199) with advanced NSCLC were treated with gefitinib (250 mg) upon progression with chemotherapy. Baseline patient characteristics were: median age, 69 years; males, 57%; adenocarcinoma, 56%. Results: Partial responses were noted in two patients (1%) and disease stabilization in 66 (35%) patients. The median survival (MS) was 5.9 months [95% confidence interval (CI) 4.1-7.1] and median time to progression was 3 months (95% CI 2.0-3.0). The predictive factors analyzed were gender, skin rash, diarrhea, tumor histology and performance status (PS). Patients who developed skin rash (any grade) had MS of 10.8 months versus 4.0 months for those without rash (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|